These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16219173

  • 1. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W, Fong C.
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [Abstract] [Full Text] [Related]

  • 2. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB.
    J Immunol; 1997 Apr 01; 158(7):3325-34. PubMed ID: 9120290
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M.
    Bone Marrow Transplant; 1998 May 01; 21(9):909-16. PubMed ID: 9613783
    [Abstract] [Full Text] [Related]

  • 5. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES, Kantor JA, Shupert WL, Schlom J, Abrams SI.
    Cell Immunol; 1998 Aug 01; 187(2):103-16. PubMed ID: 9732698
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.
    Eur J Immunol; 2006 Mar 01; 36(3):593-602. PubMed ID: 16479544
    [Abstract] [Full Text] [Related]

  • 8. Functional assays of HLA A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan.
    Lin HJ, Cherng JM, Hung MS, Sayion Y, Lin JC.
    J Biomed Sci; 2005 Dec 01; 12(6):925-36. PubMed ID: 16307312
    [Abstract] [Full Text] [Related]

  • 9. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 10. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP, Huang JQ, Zhou TC, Zhang SX, Wang JL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 15; 28(8):1431-3. PubMed ID: 18753079
    [Abstract] [Full Text] [Related]

  • 11. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 12. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI.
    Clin Immunol; 2001 Feb 20; 98(2):220-8. PubMed ID: 11161978
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.
    Cancer Res; 2001 Aug 15; 61(16):6219-26. PubMed ID: 11507075
    [Abstract] [Full Text] [Related]

  • 14. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ.
    J Immunother; 2007 Aug 15; 30(5):544-56. PubMed ID: 17589295
    [Abstract] [Full Text] [Related]

  • 15. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
    Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, Johnson PJ.
    J Med Virol; 2002 Jul 15; 67(3):359-63. PubMed ID: 12116028
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, Bharadwaj M, Khanna R.
    Blood; 2003 Apr 15; 101(8):3150-6. PubMed ID: 12468425
    [Abstract] [Full Text] [Related]

  • 17. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 18. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R, Burrows SR, Nicholls J, Poulsen LM.
    Eur J Immunol; 1998 Feb 15; 28(2):451-8. PubMed ID: 9521052
    [Abstract] [Full Text] [Related]

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
    Preta G, Marescotti D, Fortini C, Carcoforo P, Castelli C, Masucci M, Gavioli R.
    Scand J Immunol; 2008 Dec 15; 68(6):579-88. PubMed ID: 19000094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.